1. Click chemistry-mediated enrichment of circulating tumor cells and tumor-derived extracellular vesicles for dual liquid biopsy in differentiated thyroid cancer
- Author
-
Feng, Bing, Wang, Jing, Zhang, Ryan Y, Wei, Anna Yaxuan, Zhao, Chen, Yen, Ying-Tzu, Ji, You-Ren, Kim, Hyoyong, Ju, Yong, Smalley, Matthew, Zuo, Vivian Xufei, Cheng, Liwen, Phung, Aaron, Zhou, Ziang, Yu, Sitong, DiBernardo, Gabriella, Memarzadeh, Sanaz, Posadas, Edwin M, Chai-Ho, Wanxing, Agopian, Vatche, Lee, Junseok, Yeh, Michael W, Wu, James, Zheng, Guangjuan, Tseng, Hsian-Rong, and Zhu, Yazhen
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Good Health and Well Being ,Biomedical Engineering ,Nanotechnology ,Nanoscience & Nanotechnology ,Medical biotechnology ,Biomedical engineering - Abstract
Circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tEVs) are two crucial methodologies of liquid biopsy. Given their distinct size differences and release dynamics, CTCs and tEVs potentially offer synergistic capabilities in the non-invasive detection of differentiated thyroid cancer (DTC), a typically indolent tumor. We present the Combined DTC CTC/tEV Assay, integrating dual liquid biopsy processes: i) DTC CTC enrichment by Click Chips, followed by analysis of seven DTC-specific genes, and ii) DTC tEV enrichment by Click Beads, succeeded by mRNA cargo quantification in DTC tEVs. This method utilizes click chemistry, leveraging a pair of biorthogonal and highly reactive functional motifs (tetrazine, Tz, and trans-cyclooctene, TCO), to overcome the challenges encountered in the conventional immunoaffinity-based enrichment of CTCs and tEVs. The Combined DTC CTC/tEV Assay synergistically combines the diagnostic precision of CTCs with the sensitivity of tEVs, demonstrating superior diagnostic accuracy in DTC detection and boasting an AUROC of 0.99. This outperforms the individual diagnostic performance of using either DTC CTC or DTC tEV alone. This integration enables full utilization of a patient's blood sample, and marks a significant evolution in the development of nanomaterial-based liquid biopsy technologies to address challenging unmet clinical needs in cancer care.
- Published
- 2024